Review



v v endothelial cell growth medium mv2  (PromoCell)


Bioz Verified Symbol PromoCell is a verified supplier
Bioz Manufacturer Symbol PromoCell manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 98

    Structured Review

    PromoCell v v endothelial cell growth medium mv2
    V V Endothelial Cell Growth Medium Mv2, supplied by PromoCell, used in various techniques. Bioz Stars score: 98/100, based on 700 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/v v endothelial cell growth medium mv2/product/PromoCell
    Average 98 stars, based on 700 article reviews
    v v endothelial cell growth medium mv2 - by Bioz Stars, 2026-03
    98/100 stars

    Images



    Similar Products

    98
    PromoCell v v endothelial cell growth medium mv2
    V V Endothelial Cell Growth Medium Mv2, supplied by PromoCell, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/v v endothelial cell growth medium mv2/product/PromoCell
    Average 98 stars, based on 1 article reviews
    v v endothelial cell growth medium mv2 - by Bioz Stars, 2026-03
    98/100 stars
      Buy from Supplier

    98
    PromoCell v v mv2 supplement mix
    Canagliflozin inhibits 2-deoxyglucose uptake in HUVECs without influencing cell proliferation. ( a ) HUVECs were preincubated in the presence or absence of canagliflozin (10 μmol/l) for the times indicated or dapagliflozin (10 μmol/l, 30 min) and 2-deoxyglucose uptake assessed. Data shown represents the mean 2-deoxyglucose uptake relative to vehicle from three independent experiments. **p < 0.01, ***p < 0.001 relative to vehicle (one-way ANOVA). ( b ) Cell lysates from HUVECs (2 independent lysates), HAECs (4 independent lysates) and HEK-293 cells and mouse kidney membranes were resolved by SDS-PAGE and immunoblotted with anti-SGLT2 antibodies. The immunoblot shown has been cropped, with the full-length immunoblot shown in Supplementary Figure . ( c , d ) HUVECs were incubated in the presence or absence of canagliflozin, dapagliflozin or empagliflozin and ( c ) proliferation assessed in 2.5% <t>(v/v)</t> or 5% (v/v) <t>MV2</t> Supplement mix (serum) by BrdU incorporation or ( d ) viability assessed by MTS assay. Data shown represents the mean proliferation or viability relative to vehicle (in 5% MV2 supplement mix) from three independent experiments in each cae. ## p < 0.01 relative to vehicle (two-tailed t-test).
    V V Mv2 Supplement Mix, supplied by PromoCell, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/v v mv2 supplement mix/product/PromoCell
    Average 98 stars, based on 1 article reviews
    v v mv2 supplement mix - by Bioz Stars, 2026-03
    98/100 stars
      Buy from Supplier

    Image Search Results


    Canagliflozin inhibits 2-deoxyglucose uptake in HUVECs without influencing cell proliferation. ( a ) HUVECs were preincubated in the presence or absence of canagliflozin (10 μmol/l) for the times indicated or dapagliflozin (10 μmol/l, 30 min) and 2-deoxyglucose uptake assessed. Data shown represents the mean 2-deoxyglucose uptake relative to vehicle from three independent experiments. **p < 0.01, ***p < 0.001 relative to vehicle (one-way ANOVA). ( b ) Cell lysates from HUVECs (2 independent lysates), HAECs (4 independent lysates) and HEK-293 cells and mouse kidney membranes were resolved by SDS-PAGE and immunoblotted with anti-SGLT2 antibodies. The immunoblot shown has been cropped, with the full-length immunoblot shown in Supplementary Figure . ( c , d ) HUVECs were incubated in the presence or absence of canagliflozin, dapagliflozin or empagliflozin and ( c ) proliferation assessed in 2.5% (v/v) or 5% (v/v) MV2 Supplement mix (serum) by BrdU incorporation or ( d ) viability assessed by MTS assay. Data shown represents the mean proliferation or viability relative to vehicle (in 5% MV2 supplement mix) from three independent experiments in each cae. ## p < 0.01 relative to vehicle (two-tailed t-test).

    Journal: Scientific Reports

    Article Title: Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms

    doi: 10.1038/s41598-018-23420-4

    Figure Lengend Snippet: Canagliflozin inhibits 2-deoxyglucose uptake in HUVECs without influencing cell proliferation. ( a ) HUVECs were preincubated in the presence or absence of canagliflozin (10 μmol/l) for the times indicated or dapagliflozin (10 μmol/l, 30 min) and 2-deoxyglucose uptake assessed. Data shown represents the mean 2-deoxyglucose uptake relative to vehicle from three independent experiments. **p < 0.01, ***p < 0.001 relative to vehicle (one-way ANOVA). ( b ) Cell lysates from HUVECs (2 independent lysates), HAECs (4 independent lysates) and HEK-293 cells and mouse kidney membranes were resolved by SDS-PAGE and immunoblotted with anti-SGLT2 antibodies. The immunoblot shown has been cropped, with the full-length immunoblot shown in Supplementary Figure . ( c , d ) HUVECs were incubated in the presence or absence of canagliflozin, dapagliflozin or empagliflozin and ( c ) proliferation assessed in 2.5% (v/v) or 5% (v/v) MV2 Supplement mix (serum) by BrdU incorporation or ( d ) viability assessed by MTS assay. Data shown represents the mean proliferation or viability relative to vehicle (in 5% MV2 supplement mix) from three independent experiments in each cae. ## p < 0.01 relative to vehicle (two-tailed t-test).

    Article Snippet: HUVECs (2 × 10 4 cells/well) were allowed to attach to 96-well plates for 4 h in MV2 medium containing 2.5% or 5% (v/v) MV2 Supplement Mix (Promocell C-39226) containing serum and growth factors and subsequently incubated in the same medium with DMSO (vehicle) or SGLT2 inhibitors for 12 h. BrdU reagent was then added and cells further incubated for 24 h. BrdU incorporation was assessed by measuring A 485/520 on a BMG Labtech FLUOstar Optima spectrophotometer microplate reader.

    Techniques: SDS Page, Western Blot, Incubation, BrdU Incorporation Assay, MTS Assay, Two Tailed Test